Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of "Buy" by Brokerages

Shares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have received a consensus rating of "Buy" from the six analysts that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $5.50.

Several research firms have recently commented on CNTX. William Blair reissued an "outperform" rating on shares of Context Therapeutics in a report on Tuesday, April 29th. D. Boral Capital restated a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a research note on Thursday, May 8th. Finally, Piper Sandler restated an "overweight" rating and issued a $4.00 price target (down previously from $4.50) on shares of Context Therapeutics in a research note on Thursday, June 26th.

Insiders Place Their Bets

In related news, CEO Martin A. Lehr bought 100,000 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were bought at an average cost of $0.70 per share, for a total transaction of $70,000.00. Following the completion of the transaction, the chief executive officer owned 920,190 shares of the company's stock, valued at approximately $644,133. This trade represents a 12.19% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jennifer Lynn Minai-Azary acquired 40,010 shares of the stock in a transaction dated Friday, June 6th. The stock was acquired at an average price of $0.64 per share, for a total transaction of $25,606.40. Following the completion of the transaction, the chief financial officer directly owned 80,010 shares of the company's stock, valued at approximately $51,206.40. This represents a 100.03% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 160,010 shares of company stock valued at $107,206. Corporate insiders own 3.04% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Shay Capital LLC purchased a new stake in shares of Context Therapeutics during the 4th quarter valued at $52,000. MPM Bioimpact LLC acquired a new position in shares of Context Therapeutics in the fourth quarter valued at about $15,441,000. Millennium Management LLC raised its stake in shares of Context Therapeutics by 24.2% in the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company's stock worth $188,000 after purchasing an additional 34,835 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics during the fourth quarter worth about $31,000. Finally, Allostery Investments LP purchased a new stake in Context Therapeutics in the fourth quarter valued at approximately $998,000. Institutional investors own 14.03% of the company's stock.

Context Therapeutics Trading Down 4.8%

Shares of CNTX traded down $0.04 during midday trading on Monday, hitting $0.83. The stock had a trading volume of 202,608 shares, compared to its average volume of 278,738. Context Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $2.75. The business has a 50-day simple moving average of $0.67 and a two-hundred day simple moving average of $0.78. The firm has a market cap of $74.20 million, a P/E ratio of -2.67 and a beta of 1.88.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05). On average, analysts expect that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.